KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Short-term Investments (2021 - 2026)

AbCellera Biologics filings provide 6 years of Short-term Investments readings, the most recent being $25.0 million for Q1 2026.

  • Quarterly Short-term Investments changed 0.0% to $25.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $25.0 million through Mar 2026, changed 0.0% year-over-year, with the annual reading at $25.0 million for FY2025, 0.0% changed from the prior year.
  • Short-term Investments hit $25.0 million in Q1 2026 for AbCellera Biologics, roughly flat from $25.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $25.0 million in Q4 2022 and bottomed at $25.0 million in Q4 2022.
  • Average Short-term Investments over 5 years is $25.0 million, with a median of $25.0 million recorded in 2022.
  • Peak annual rise in Short-term Investments hit 0.0% in 2022, while the deepest fall reached 0.0% in 2022.
  • AbCellera Biologics' Short-term Investments stood at $25.0 million in 2022, then changed by 0.0% to $25.0 million in 2023, then changed by 0.0% to $25.0 million in 2024, then changed by 0.0% to $25.0 million in 2025, then changed by 0.0% to $25.0 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Short-term Investments are $25.0 million (Q1 2026), $25.0 million (Q4 2025), and $25.0 million (Q3 2025).